489 results on '"Lu, Peihua"'
Search Results
2. Targeting nucleotide metabolic pathways in colorectal cancer by integrating scRNA-seq, spatial transcriptome, and bulk RNA-seq data
3. Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL
4. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia
5. Distinct Requirements for Adaptor Proteins NCK1 and NCK2 in Mammary Gland Development
6. Acetylation halts missense mutant p53 aggregation and rescues tumor suppression in non-small cell lung cancers
7. Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR
8. CAR T-cell therapies in China: rapid evolution and a bright future
9. ZEB1: Catalyst of immune escape during tumor metastasis
10. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial
11. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
12. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
13. CAR-T and other adoptive cell therapies for B cell malignancies
14. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
15. Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.
16. Immunotherapeutic silk inverse opal particles for post-surgical tumor treatment
17. Complementary Nck1/2 Signaling in Podocytes Controls α Actinin-4–Mediated Actin Organization, Adhesion, and Basement Membrane Composition
18. Advances towards genome‐based acute myeloid leukemia classification: A comparative analysis of WHO‐HAEM4R, WHO‐HAEM5, and International Consensus Classification
19. Companion gene mutations and their clinical significance in AML with double mutant CEBPA
20. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations
21. De Novo MET Amplification in Chinese Patients With Non–Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study
22. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China
23. Detection of rare malignant cells in gastric lavage using Hexokinase 2 and single-cell sequencing for early-stage gastric cancer diagnosis
24. Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7‐targeted chimeric antigen receptor‐T cell therapy
25. P1170: CAR-T THERAPY IS EFFECTIVE AND SAFE IN TREATING RELAPSED/REFRACTORY LYMPHOMA WITH MALIGNANT SEROUS CAVITY EFFUSION
26. P392: FEATURES AND TREATMENT OF PATIENTS WITH T(8;14)(Q24;Q11)/ TCRA/D::MYC TRANSLOCATED T ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/LBL)
27. P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
28. P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
29. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
30. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
31. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
32. Supplementary Data from Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies
33. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
34. DNTT activation, TdT‐aided gene length mutation, and better prognosis in ATG‐based regimen allo‐HSCT in AML
35. Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson’s disease
36. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study
37. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia
38. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
39. Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy
40. Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia
41. Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant
42. A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma
43. The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
44. Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr
45. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication
46. Genetic variations in PRKAA1 predict the risk and progression of gastric Cancer
47. Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation
48. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
49. The positive regulatory loop of TCF4N/p65 promotes glioblastoma tumourigenesis and chemosensitivity
50. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.